Anti-VEGF Antibody Leads to Later Atypical Intravitreous Neovascularization and Activation of Angiogenic Pathways in a Rat Model of Retinopathy of Prematurity
Authors:
- Haibo WangHWHaibo Wang
- Yanchao JiangYJYanchao Jiang
- George Wesley SmithGSGeorge Wesley Smith
- Jeremy StrangeJSJeremy Strange
- M. Elizabeth HartnettMHM. Elizabeth Hartnett
Open Access
- 1 March 2013
- journal article
- retina
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 54 (3) , 2020-2026
Abstract
Purpose.: Inhibiting VEGF improves adult retino/choroido-vascular diseases, but can lead to recurrent intravitreous neovascularization (IVNV), avascular retina (AVA), and retinal detachment in preterm infants with retinopathy of prematurity (ROP). We sought to understand causes of late-onset IVNV and AVA following anti-VEGF using an ROP model. Methods.: In the Penn model of ROP, postnatal day (p)12 pups received 1 μL intravitreal VEGFA164 antibody (anti-VEGF; 25–100 ng) or IgG control in each eye. Analyses included lectin-stained percent IVNV and AVA; VEGF protein, erythropoietin, phosphorylated extracellular signal-related kinases and signal transducer and activator of transcription-3 (p-STAT3); and immunohistochemistry of retinal sections for p-VEGFR2. Western blots of human retinal microvascular endothelial cells (hRMVECs) stimulated with VEGF or erythropoietin were analyzed for p-STAT3. Statistical analysis was performed with one-way ANOVA or two-tailed t-tests. Results.: At p18, 50 ng anti-VEGF reduced IVNV, and at p25, caused increased IVNV and AVA compared with controls. VEGF and p-VEGFR2 labeling increased following 100 ng anti-VEGF. Following 50 ng anti-VEGF, reduced p-STAT3 and increased erythropoietin occurred at p18. Erythropoietin or VEGF stimulated hRMVEC proliferation and STAT3 activation. In vivo, anti-VEGF reduced pup growth. Conclusions.: Increases in erythropoietin and angiogenic signaling following anti-VEGF may account for recurrent IVNV. Anti-VEGF reduced pup growth. Research is needed regarding safety, dose, and type of antiangiogenic treatment for ROP.Keywords
This publication has 33 references indexed in Scilit:
- Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of PrematurityNew England Journal of Medicine, 2011
- Therapeutic targets in age-related macular diseaseJournal of Clinical Investigation, 2010
- A review of clinical trials of anti-VEGF agents for diabetic retinopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2010
- Antiangiogenic agents and HIF-1 inhibitors meet at the crossroadsCell Cycle, 2009
- Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROPExperimental Eye Research, 2009
- Higher Cumulative Doses of Erythropoietin and Developmental Outcomes in Preterm InfantsPediatrics, 2009
- Vitreous Levels of Erythropoietin and Vascular Endothelial Growth Factor in Eyes with Retinopathy of PrematurityOphthalmology, 2009
- The Role of Supplemental Oxygen and JAK/STAT Signaling in Intravitreous Neovascularization in a ROP Rat ModelInvestigative Ophthalmology & Visual Science, 2009
- Suppression of Retinal Neovascularization by Erythropoietin siRNA in a Mouse Model of Proliferative RetinopathyInvestigative Ophthalmology & Visual Science, 2009
- Human recombinant erythropoietin and the incidence of retinopathy of prematurity: A multiple regression modelJournal of American Association for Pediatric Ophthalmology and Strabismus, 2008